X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aged (4) 4
female (4) 4
humans (4) 4
male (4) 4
middle aged (4) 4
adult (3) 3
care and treatment (3) 3
dexamethasone (3) 3
disease-free survival (3) 3
hematology (3) 3
index medicus (3) 3
kaplan-meier estimate (3) 3
treatment outcome (3) 3
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
bortezomib (2) 2
cancer (2) 2
chemotherapy (2) 2
cyclophosphamide (2) 2
doxorubicin - adverse effects (2) 2
doxorubicin - analogs & derivatives (2) 2
doxorubicin - therapeutic use (2) 2
elderly-patients (2) 2
follow-up studies (2) 2
hematology, oncology and palliative medicine (2) 2
medical colleges (2) 2
multiple myeloma (2) 2
multiple myeloma - mortality (2) 2
oncology (2) 2
pegylated liposomal doxorubicin (2) 2
polyethylene glycols - adverse effects (2) 2
polyethylene glycols - therapeutic use (2) 2
prednisone (2) 2
product development (2) 2
remission induction (2) 2
survival analysis (2) 2
thalidomide (2) 2
transplantation (2) 2
transplants & implants (2) 2
administration, oral (1) 1
aged, 80 and over (1) 1
analysis (1) 1
anthracyclines (1) 1
anti-cd20 antibody rituximab (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
australia (1) 1
bleomycin (1) 1
bone marrow (1) 1
boronic acids - administration & dosage (1) 1
borrelia-burgdorferi (1) 1
chemotherapy, adjuvant (1) 1
clinical trials (1) 1
clinicopathological features (1) 1
combination (1) 1
combination therapy (1) 1
combined modality therapy (1) 1
consolidation therapy (1) 1
cyclophosphamide - therapeutic use (1) 1
czech republic (1) 1
dexamethasone - administration & dosage (1) 1
dexamethasone - therapeutic use (1) 1
dexamethasone combination (1) 1
disease progression (1) 1
diseases (1) 1
dose-response relationship, drug (1) 1
double-blind method (1) 1
doxorubicin - administration & dosage (1) 1
drug administration schedule (1) 1
drug dosages (1) 1
drug therapy (1) 1
etoposide (1) 1
follow-up (1) 1
heart attacks (1) 1
hematopoietic stem cell transplantation - adverse effects (1) 1
hematopoietic stem cell transplantation - mortality (1) 1
hydroxamic acids - administration & dosage (1) 1
indoles - administration & dosage (1) 1
induction (1) 1
infusions, intravenous (1) 1
inhibitor panobinostat (1) 1
initial treatment (1) 1
italy (1) 1
lbh589 (1) 1
lenalidomide (1) 1
liposomes - administration & dosage (1) 1
lymphoma, b-cell - drug therapy (1) 1
lymphoma, b-cell - pathology (1) 1
lymphoma, t-cell, cutaneous - drug therapy (1) 1
maintenance chemotherapy (1) 1
maximum tolerated dose (1) 1
melphalan (1) 1
melphalan - therapeutic use (1) 1
monochemotherapy (1) 1
multiple myeloma - diagnosis (1) 1
multiple myeloma - drug therapy (1) 1
multiple myeloma - pathology (1) 1
multiple myeloma - therapy (1) 1
mycosis fungoides (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1617 - 1629
Summary Background High-dose melphalan plus autologous stem-cell transplantation (ASCT) is the standard approach in transplant-eligible patients with newly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | ONCOLOGY | CONSOLIDATION THERAPY | INITIAL TREATMENT | THALIDOMIDE | BORTEZOMIB | INDUCTION | STEM-CELL TRANSPLANTATION | DEXAMETHASONE COMBINATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Melphalan - therapeutic use | Hematopoietic Stem Cell Transplantation - mortality | Cyclophosphamide - therapeutic use | Thalidomide - analogs & derivatives | Multiple Myeloma - therapy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Maintenance Chemotherapy | Chemotherapy, Adjuvant | Thalidomide - adverse effects | Prednisone - adverse effects | Multiple Myeloma - diagnosis | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Disease-Free Survival | Czech Republic | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Thalidomide - therapeutic use | Australia | Prednisone - therapeutic use | Medical colleges | Cyclophosphamide | Care and treatment | Chemotherapy | Dexamethasone | Multiple myeloma | Stem cells | Product development | Prednisone | Transplantation | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1195 - 1206
Journal Article
Haematologica, ISSN 0390-6078, 05/2007, Volume 92, Issue 5, pp. 686 - 689
Journal Article
European Journal of Haematology, ISSN 0902-4441, 03/2009, Volume 82, Issue 3, pp. 184 - 193
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.